Innate Pharma

Report Publication Announcement • Dec 8, 2014

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2015 AS WELL AS ITS PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

Marseille, France, December 02, 2014

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:

• February 19, 2015: Publication of 2014 financial statements, with management comments. The 2014 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2015
• April 27, 2015: Annual shareholders meeting in Marseille
• May 5, 2015: Publication of revenue for 1Q2015, with management comments
• September 17, 2015: Publication of financial statements as of June 30, 2015, with management comments
• November 5, 2015: Publication of revenue for 3Q2015, with management comments

In the first quarter of 2015, Innate Pharma management will be present at the following investor conferences:

• Oddo Midcap Forum Lyon, January 8-9, 2015
• J.P. Morgan 33rd Annual Healthcare Conference San Francisco, CA, January 12- 15, 2015
• Leerink Global Healthcare Conference New York, NY, February 11-12, 2015
• Credit Suisse Global Healthcare Conference London, March 3-4, 2015

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (www.innatepharma.com/en/financials).

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and Novo Nordisk A/S.

The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma science also has potential in chronic inflammatory diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 97 employees as at September 30, 2014.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website (www.innate-pharma.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press

Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 investors@innate-pharma.com presse@atcg-partners.com

Judith Aziza, Mob.:+33 (0)6 70 07 77 51 Marielle Bricman, Mob.:+33 (0)6 26 94 18 53